ENGELHARDT, JOHN,英吉哈特 约翰,英吉哈特 約翰,SELBY, MARK J.,赛尔比 马克 J,賽爾比 馬克 J,KORMAN, ALAN J.,寇曼 亚兰 J,寇曼 亞蘭 J,FEINGERSH, MARY DIANE,费格许 玛莉 黛安,費格許 瑪莉 黛安,STEVENS, BRENDA L.,史帝芬斯 布兰达 L,史帝芬斯 布蘭達 L,英吉哈特 约翰,英吉哈特 約翰,赛尔比 马克 J,賽爾比 馬克 J,寇曼 亚兰 J,寇曼 亞蘭 J,费格许 玛莉 黛安,費格許 瑪莉 黛安,史帝芬斯 布兰达 L,史帝芬斯 布蘭達 L
申请号：
TW107111620
公开号：
TW201843173A
申请日:
2018.04.02
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in a broad variety of therapeutic applications, such as to treat cancer, as well as be used in methods to detect ICOS protein.本發明提供經分離之單株抗體(例如，人類化及人類單株抗體)，其結合至人類可誘導T細胞共刺激分子(ICOS)並顯示治療所需之功能性質(例如，刺激人類ICOS活性之能力)。亦提供編碼本發明之抗體之核酸分子、用於表現本發明之抗體之表現載體、宿主細胞及方法。亦提供包含本發明之抗體之免疫結合物、雙特異性分子及醫藥組合物。本發明之抗體(例如)可用作促效劑以刺激或增強個體之免疫反應，例如，對抗腫瘤或病毒抗原之抗原特異性T細胞反應。本發明之抗體亦可與其他抗體(例如，PD-1、PD-L1及/或CTLA-4抗體)組合使用以治療(例如)癌症。因此，該等抗體可用於各種各樣之治療應用中(諸如用以治療癌症)及用於用以偵測ICOS蛋白之方法中。
